Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients

被引：0

作者：

Blanc-Durand, F. ^{[1
]}

Auclin, E. ^{[2
]}

Planchard, D. ^{[1
]}

Ponce Aix, S. ^{[3
]}

Hendriks, L. ^{[4
]}

Sullivan, I. G. ^{[5
]}

Saravia, D. ^{[6
]}

Routy, B. ^{[7
]}

Lopez Castro, R. ^{[8
]}

Pilotto, S. ^{[9
]}

Aboubakar, F. ^{[10
]}

Kassouf, E. ^{[11
]}

Rodriguez, A. ^{[12
]}

Amores Martin, A. ^{[13
]}

Bluthgen, M. V. ^{[14
]}

Duchemann, B. ^{[15
]}

Caramella, C. ^{[16
]}

Nadal, E. ^{[17
]}

Besse, B. ^{[1
]}

Mezquita, L. ^{[1
]}

机构：

[1] Inst Gustave Roussy, Med Oncol, Villejuif, France

[2] Hop European George Pompidou, Gastrointestinal & Med Oncol Dept, Paris, France

[3] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain

[4] Maastricht Univ, Med Ctr, Pulm Dis, Maastricht, Netherlands

[5] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[6] Jackson Mem Hosp, Hematol Oncol Dept, Miami, FL 33136 USA

[7] Univ Montreal, Res Ctr, Hematooncol, Montreal, PQ, Canada

[8] Univ Clin Hosp Valladolid, Med Oncol, Valladolid, Spain

[9] AOU Integrata Borgo Roma Verona, Med Oncol, Verona, Italy

[10] UC Louvain Brussels Woluwe, Dept Oncol Thorac, Brussels, Belgium

[11] Ctr Hosp Reg Lanaudiere, Med Oncol, St Charles Borromee, PQ, Canada

[12] Inst Clin Malalties Hematol & Oncol, Med Oncol, Barcelona, Spain

[13] Hosp Clin Univ Salamanca, Med Oncol, Salamanca, Spain

[14] Hosp Aleman, Med Oncol, Buenos Aires, DF, Argentina

[15] Hop Avicenne, Med Oncol, Bobigny, France

[16] Inst Gustave Roussy, Radiol, Villejuif, France

[17] ICO, Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

17P

引用

页码：5 / 5

页数：1

共 50 条

[11] Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
Proto, C.
Chiaruttini, M. V.
Prelaj, A.
Lo Russo, G.
Ferrara, R.
Manglaviti, S.
De Toma, A.
Brambilla, M.
Occhipinti, M.
Beninato, T.
Mazzeo, L.
Pircher, C.
Dumitrascu, A. D.
de Braud, F.
Segale, M.
Garassino, M. C.
Sozzi, G.
Porcu, L.
Rulli, E.
Boeri, M.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S119 - S120
[12] Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)
Mielgo Rubio, X.
Gomez Rueda, A.
Antonanzas, M.
Falagan, S.
Nunez, J. A.
Pena, A. M. Sanchez
Gomez-Barreda, I.
Martinez Moreno, E.
Cerezo Gonzalez, S.
Cabezon Gutierrez, L.
Sanchez Torres, J. M.
Jimenez Munarriz, B. E.
Cervera, R.
Pangua Mendez, C.
Calles Blanco, A.
Lopez Martin, A.
Lopez Castro, R.
Sotelo Lezama, M. J.
Perez Fernandez, E.
Cruz, P.
ANNALS OF ONCOLOGY, 2019, 30
[13] Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
Wan, Mingyu
Ding, Yongfeng
Mao, Chenyu
Ma, Xiaolu
Li, Ning
Xiao, Cheng
Qian, Jiong
Jiang, Haiping
Zheng, Yulong
Wu, Luntao
Teng, Lisong
Xu, Nong
FRONTIERS IN ONCOLOGY, 2022, 12
[14] The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
Meyers, Daniel E.
Stukalin, Igor
Vallerand, Isabelle A.
Lewinson, Ryan T.
Suo, Aleksi
Dean, Michelle
North, Scott
Pabani, Aliyah
Cheng, Tina
Heng, Daniel Y. C.
Bebb, D. Gwyn
Morris, Don G.
CANCERS, 2019, 11 (11)
[15] The lung-immune prognostic index (LIPI) to predict early mortality among patients affected by advanced solid cancers under immune-checkpoint inhibitors treatments
De Giglio, Andrea
Filippini, Daria Maria
Mollica, Veronica
Rihawi, Karim
Comito, Francesca
Carosi, Francesca
Marchetti, Andrea
Ricciotti, Ilaria
Gelsomino, Francesco
Nobili, Elisabetta
Melotti, Barbara
Sperandi, Francesca
Massari, Francesco
Pantaleo, Maria A.
Ardizzoni, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[16] Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
Lefebvre, C.
Martin, E.
Hendriks, L. E. L.
Veillon, R.
Puisset, F.
Mezquita, L.
Ferrara, R.
Sabatier, M.
Filleron, T.
Dingemans, A-M C.
Besse, B.
Raherisson, C.
Mazieres, J.
RESPIRATORY MEDICINE AND RESEARCH, 2020, 78
[17] Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy
Lefebvre, C.
Martin, E.
Hendriks, L.
Veillon, R.
Filleron, T.
Puisset, F.
Mezquita, L.
Ferrara, R.
Sabatier, M.
Besse, B.
Dingemans, A. M.
Mazieres, J.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S409 - S409
[18] Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
Sun, Tao
Guo, Yusheng
Sun, Bo
Chen, Lei
Ren, Yanqiao
Zhu, Licheng
Zhang, Lijie
Liu, Yiming
Zheng, Chuansheng
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
[19] Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
Tao Sun
Yusheng Guo
Bo Sun
Lei Chen
Yanqiao Ren
Licheng Zhu
Lijie Zhang
Yiming Liu
Chuansheng Zheng
European Journal of Medical Research, 28
[20] Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
Petrelli, Fausto
Ferrara, Roberto
Signorelli, Diego
Ghidini, Antonio
Proto, Claudia
Roudi, Raheleh
Sabet, Mehrdad N.
Facelli, Sara
Garassino, Marina C.
Luciani, Andrea
Roviello, Giandomenico
IMMUNOTHERAPY, 2021, 13 (07) : 621 - 632

← 1 2 3 4 5 →